ABSI vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

ABSI

47.1
AI Score
VS
ABSI Wins

XBIO

36.5
AI Score

Investment Advisor Scores

ABSI

47score
Recommendation
HOLD

XBIO

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ABSI XBIO Winner
Revenue 3.87M 1.47M ABSI
Net Income -74.12M -1.39M XBIO
Net Margin -1915.8% -94.5% XBIO
Operating Income -79.11M -1.47M XBIO
ROE -36.8% -22.8% XBIO
ROA -31.5% -19.9% XBIO
Total Assets 235.23M 6.97M ABSI
Current Ratio 5.63 7.43 XBIO

Relative Price Performance (Last 90 Days)

ABSI 1M: -13.6% · 3M: +26.1% XBIO 1M: +18.2% · 3M: +30.0%

Current Technical Phase

ABSI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 42

RSI (14): 41.8 · Price: $8.21

XBIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (12.0% over 20 days), RSI 54

RSI (14): 53.7 · Price: $3.90

Fundamentals Snapshot

Metric ABSI XBIO
Market Cap
Forward P/E -12.2 -11.5
Trailing P/E
Revenue (TTM)
Revenue Growth -0.5% 0.1%
Gross Margin -54.0% 1.0%
Operating Margin -107.4% -1.5%
EPS -0.75 -1.15
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ABSI is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.